Peptide Codes Forum

So I've been sitting on this post for about three weeks now because I wanted to make sure I wasn't just reacting emotionally and that I had enough data points to say something worth saying. I'm not going to name the supplier directly in this post for reasons I'll explain, but anyone who's been around long enough will probably be able to put two and two together based on the details.

Background: I've been running various GH secretagogue stacks for roughly four years. Currently interested in GHRP-2/CJC-1295 no DAC combinations, have also run ipamorelin based stacks. I know what a properly dosed, properly reconstituted stack feels like at baseline. I'm not coming at this from zero experience.

Here's the issue. About six weeks ago I sourced from a vendor that has been getting a lot of positive attention in several threads here and on the other forums I lurk. New-ish reputation, aggressive pricing, flashy website, lots of glowing reviews from accounts that were created within the last eight months. Red flags I noted but chose to partially ignore because the pricing was genuinely compelling and I wanted to test them myself rather than just parrot other people's assessments.

What I received - GHRP-2 at supposedly 5mg per vial and CJC no DAC at supposedly 2mg per vial. Lyophilized, appeared visually normal. Reconstitution went fine. This is where things started going sideways.

At doses that have historically produced reliable and noticeable physiological responses for me - we're talking the expected transient hunger signal from GHRP-2 especially, slight flushing, the subjective "pulse" feeling some researchers describe - I got essentially nothing. Not subtle, not blunted. Nothing. And before anyone asks the obvious questions: yes, proper reconstitution, yes appropriate bacteriostatic water, yes timing relative to food intake was controlled, yes injection protocol was consistent. I've been doing this long enough that I'm not making beginner mistakes.

Now here's where I want to be analytically precise rather than just ranting. There are multiple possible explanations for this and I want to walk through them because I think people on forums jump to conclusions too fast.

Possibility one: the peptides were degraded prior to my receiving them. This is actually my primary hypothesis. If storage and shipping conditions were inadequate - and this is a known, chronic problem across the entire space, not unique to any one vendor - lyophilized product can still look completely normal while having undergone significant degradation. You cannot visually assess potency of a lyophilized peptide. This is something I feel like gets repeated constantly but somehow people still don't internalize it. Temperature excursions during transit, improper cold chain management, product sitting in a non-climate controlled warehouse somewhere - any of these can kill potency without leaving visible evidence. My particular suspicion here is shipping, because the packaging this vendor uses is not adequate for summer transit in my region. Insulated but not with sufficient ice pack mass for more than about 24-36 hours. My order took four days to arrive.

Possibility two: the vials were underdosed to begin with. I can't rule this out. Without third party HPLC testing I cannot rule it out at all. And this is the deeply frustrating structural problem with this entire space. The verification mechanisms available to most individual researchers are essentially nonexistent at the point of purchase. You are relying on trust and reputation, both of which can be manufactured or gamed, as I suspect is happening with this particular vendor's review ecosystem.

Possibility three: it's me. I always have to put this on the table. Receptor downregulation, changes in my own physiological baseline, some variable I haven't accounted for. I'm giving this maybe a 15% probability based on the fact that I ran a small amount of material from a supplier I've used for two years in parallel and got expected responses within 48 hours. So I haven't eliminated myself as a variable entirely but the comparative data points pretty strongly away from this explanation.

Possibility three: something else entirely in the formulation. Peptides synthesized with poor purity, incorrect sequences, counterfeits. Again, without analytical chemistry this is speculation but it's not paranoid speculation. There are known cases.

Now on to the dosing information problem which is a separate complaint but related. This vendor's website has dosing guidance that is internally inconsistent and in some places contradicts established literature in ways that suggest it was written by someone with either very superficial knowledge or a specific commercial interest in pushing higher usage rates. Recommending starting GHRP-2 at doses that I would consider high end of moderate as if they're conservative starting points. This could be incompetence. It could also be a strategy to make underdosed product appear to work at the dosage levels they're recommending. I'm not saying that's definitely what's happening. I'm saying the incentive structure for a vendor selling underdosed product would align perfectly with providing dosing guidance that conveniently requires more product use.

The price point they launched with was actually reasonable. In the last eight weeks since they've been getting positive attention, prices have increased noticeably. Classic pattern. Get traction with competitive pricing, build apparent reputation, increase margins. I've watched this cycle happen with multiple vendors over the years.

What I would tell people who are newer to this: the fact that a vendor has reviews does not mean the reviews are trustworthy. The fact that a price seems fair or even cheap should make you more suspicious not less, initially. The correlation between very cheap peptides and quality problems is not perfect but it's real. And for any GH secretagogue stack specifically, you should be establishing your own baseline with verified material before switching to any new source, precisely so you can do the kind of comparison I'm describing. If you don't have a reference point you have no ability to evaluate what you're getting.

I'm not saying don't use new vendors ever. I'm saying apply appropriate skepticism, understand the limitations of your ability to verify what you're receiving, and be very cautious about any vendor whose review profile looks like it materialized quickly and uniformly.

More to come if I get HPLC results back which I'm pursuing through a connection, though that will take a while. Will update this thread.

SupplierSkeptic99 wrote:Recommending starting GHRP-2 at doses that I would consider high end of moderate as if they're conservative starting points. This could be incompetence. It could also be a strategy to make underdosed product appear to work at the dosage levels they're recommending.

I have to be direct with you here, and I want to be clear that my disagreement is substantive, not personal. But this particular section of your post, and frankly some of the analytical framework you've applied throughout, contains reasoning errors that I think need to be addressed publicly because other researchers reading this thread may internalize conclusions that aren't well supported.

Let me start with what I AGREE with because I want to be fair: the cold chain problem is real, documented, and chronically underappreciated. GHRP-2 in particular shows meaningful degradation under temperature stress conditions that would leave lyophilized product visually indistinguishable from intact product. You are correct about this and it is not discussed enough. Studies examining GHRP stability under varying temperature conditions have consistently demonstrated this is not a trivial concern.

Now here is where I have to push back firmly.

Your probability assignment methodology is troubling.

You assign "possibility three" - that the variable is YOU - approximately 15% probability, and your primary reasoning for discounting this is that you ran material from a two-year trusted vendor "in parallel" and got expected responses within 48 hours. Do you understand how many confounding variables that comparison contains? The order of administration, the time elapsed between them, potential cumulative receptor sensitization from one product affecting response to another, diet and sleep differences across those days, cortisol variability. A two-point anecdotal parallel comparison is NOT controlled data. It is suggestive at best. I'm not saying you're wrong about the vendor's product quality. I'm saying your confidence level is not justified by the methodology you've described.

The dosing inference is where I'm genuinely frustrated.</b>

You are building a fairly serious allegation - that this vendor is DELIBERATELY providing inflated dosing guidance as a strategy to conceal underdosed product - on essentially no direct evidence. The alternative and frankly far more parsimonious explanation is that dosing recommendations in this space are wildly inconsistent across sources generally, and that a vendor with superficial biochemical knowledge simply copied or synthesized recommendations from inconsistent sources. I have seen GHRP-2 starting dose recommendations ranging from 50mcg to 300mcg across peer-reviewed adjacent literature, vendor sites, and forum consensus. The variance is enormous. Your inference requires attributing intentional commercial strategy to what could very easily be ordinary incompetence or sourcing from low quality secondary information.

I want to be clear: I am NOT defending this vendor. I have no idea who you are describing and I have no stake in any vendor's reputation. What I AM defending is the principle that when we are making serious allegations about intentional misconduct versus negligence, the standard of evidence should be higher than "the incentive structure would align with this behavior." Many behaviors are incentive-compatible without being the result of deliberate strategy.

The review ecosystem concern is legitimate and I will grant you that entirely. Astroturfing is documented behavior in this space and new account clustering in review profiles is a legitimate signal worth attending to. On this point your pattern recognition seems sound.

What I would ask you to consider, and what I think would make this thread genuinely more valuable to the research community: Wait for the HPLC results before framing this as an intentional fraud narrative. If the HPLC comes back showing significant sequence deviation, wrong peptide, or concentration well below labeled amount, you have a story. If it comes back showing degradation products consistent with temperature exposure, you have a cold chain story. Those are meaningfully different situations that warrant different conclusions and different warnings to the community.

Right now you have a plausible quality concern and an unfalsified but highly speculative intentional misconduct hypothesis. Please be precise about which of those you are asserting.

ok so i been reading this whole thread and i gotta say something bout dr_peptide_curious's post specifically

dr_peptide_curious wrote:You are building a fairly serious allegation - that this vendor is DELIBERATELY providing inflated dosing guidance as a strategy to conceal underdosed product - on essentially no direct evidence.

bro.... where are you getting this interpretation from lol. go back and re-read what SupplierSkeptic99 actually wrote. he literally said "I'm not saying that's definitely what's happening. I'm saying the incentive structure would align." that is NOT the same as making a deliberate fraud allegation. you're arguing against a claim he didn't actually make and then patting yourself on the back for being "precise." cmon man

also the whole breakdown of his parallel comparison methodology is way overthought. nobody here is submitting to a peer reviewed journal. hes saying he ran known good product alongside the suspect product and got completely different responses. is it perfect controlled data? obviously not. but its WAY more useful signal than nothing and its exactly what any experienced researcher should be doing when evaluating new sources. writing 3 paragraphs picking apart his anecdotal methodology when the guy is just sharing field experience feels like you're trying to win points more than actually help anyone

the part that actually bugs me is you basically told him to wait for HPLC before saying ANYTHING meaningful. but HPLC takes weeks or months for most people, vendors keep selling product in the meantime, and newer guys keep buying it. so what, everyone just stays quiet while potentially garbage product keeps moving? that makes zero sense from a community standpoint

SupplierSkeptic99's post was honestly pretty measured. the cold chain point, the review ecosystem flags, establishing a baseline before switching sources - all solid practical stuff that newer peps should actually read carefully

the main thing i will say is yeah def wait for those HPLC results before going nuclear on naming names. that part makes sense. but calling out the overall pattern and telling people to be careful? thats exactly what these threads are FOR lol

yo this whole thread is a good read honestly and i gotta throw my own experience in here because it lines up pretty closely with what SupplierSkeptic99 is describing

ran into almost the exact same situation like 8 months ago. new vendor, decent prices, looked legit on the surface. ordered ghrp-2 and ipamorelin stack. reconstituted everything correctly, timing was on point, fasted state injections the whole deal. and just... nothing. like that GHRP-2 hunger hit that you pretty much ALWAYS get when the stuff is real and dosed right?? completely absent. that was my first big red flag

SupplierSkeptic99 wrote:My particular suspicion here is shipping, because the packaging this vendor uses is not adequate for summer transit in my region. Insulated but not with sufficient ice pack mass for more than about 24-36 hours. My order took four days to arrive.

THIS. this is so underrated as a failure point. my order back then also came in basically a glorified bubble mailer with one of those tiny ice packs that was room temp by the time it got to me. took 5 days. summer shipping is no joke and so many of these vendors are genuinely clueless about it or just dont care

the parallel comparison method SupplierSkeptic99 did is honestly exactly what i did too and yeah dr_peptide_curious i get what youre saying about confounds but like... when youre an experienced researcher and you go from zero response to OBVIOUS response just by switching product the conclusion kinda writes itself lol. not peer review quality sure but its not nothing either

bottom line from my experience - the hunger signal from GHRP-2 specifically is basically your built in quality test. if youre getting zero of that at reasonable doses something is WRONG with the product. whether its degradation from bad shipping or underdosing or whatever else, doesnt really matter at that point, the product is not doing what it should

appreciate threads like this honestly. more people need to share actual field experience instead of just hype posting about sources

IronGutPeptideBro wrote:the hunger signal from GHRP-2 specifically is basically your built in quality test. if youre getting zero of that at reasonable doses something is WRONG with the product.

This. The ghrelin mimetic effect of GHRP-2 is about as reliable a functional indicator as you're going to get without actual assay equipment. Not perfect, receptor sensitivity varies person to person, but total absence at reasonable doses in an experienced user is not a nothing signal. It's a loud signal.

gainz_peptide_bro also made the point I was going to make about dr_peptide_curious's post. The "wait for HPLC" advice is academically tidy and practically useless when product is actively moving. You flag what you observe, you caveat what you don't know, you let the community factor it in. SupplierSkeptic99 did exactly that. The post was measured.

The cold chain piece is the part I want to underline one more time because it genuinely doesn't get enough attention. Summer transit in a bubble mailer with a joke ice pack is not a storage condition, it's a degradation condition. Lyophilized doesn't mean indestructible. It means more stable than reconstituted. Still has real thermal limits. If a vendor is shipping in July with a pack that's good for 24 hours and your order takes four days, you already lost.

Good thread. Wait for the HPLC and report back.

IronGutPeptideBro wrote:the hunger signal from GHRP-2 specifically is basically your built in quality test. if youre getting zero of that at reasonable doses something is WRONG with the product.

Okay this is exactly what I came here to ask about because this thread is SO valuable and I've been going back and forth on something related that I need to get more clarity on.

I've been running an ipamorelin/CJC-1295 no DAC stack for my current protocol (heavily influenced by what I've been hearing on the Huberman adjacent spaces around GH optimization and sleep architecture, shoutout to the conversations around peptide timing and circadian rhythm that have been circulating lately) - and the reason I actually gravitated toward ipamorelin over GHRP-2 was precisely BECAUSE ipamorelin doesn't produce that pronounced hunger signal. That was presented to me as a feature, not a bug - cleaner pulse, less cortisol and prolactin side effect profile, more targeted.

But reading this thread I'm realizing that by choosing the "cleaner" peptide I've actually lost my most accessible real-world quality indicator. Which is kind of a frustrating tradeoff I hadn't really thought about.

So my genuine follow-up question to anyone with more experience here, especially SupplierSkeptic99 or GrumpyOldResearcher - what are the reliable functional indicators for ipamorelin specifically when you're trying to evaluate product quality without access to HPLC? Like is there an equivalent "loud signal" the way the GHRP-2 hunger hit is? Sleep depth and quality improvements are what most people point to but that feels like such a noisy variable with so many confounders. Temperature, stress, alcohol, all of it affects sleep. Using sleep quality as your primary quality indicator for ipamorelin feels like trying to measure something precise with a really blurry ruler.

Has anyone developed a more reliable subjective marker they actually trust for ipamorelin quality assessment? Or is the honest answer that you really are flying more blind with that compound from an end-user verification standpoint?

GrumpyOldResearcher wrote:The cold chain piece is the part I want to underline one more time because it genuinely doesn't get enough attention. Summer transit in a bubble mailer with a joke ice pack is not a storage condition, it's a degradation condition.

Okay I just have to say - "a storage condition, it's a degradation condition" is genuinely the most poetic thing anyone has ever written on this forum and I want it on a t-shirt. Someone make that merch. Peptide community needs branded apparel and that's our slogan.

Sorry I know that's not helpful. Back to lurking my own thread lol.

biohack_bella_87 wrote:what are the reliable functional indicators for ipamorelin specifically when you're trying to evaluate product quality without access to HPLC? Like is there an equivalent "loud signal" the way the GHRP-2 hunger hit is?

This is a genuinely good question and I want to engage with it seriously, though I will say upfront that my answer may be somewhat less satisfying than what you are hoping to hear.

The honest reality is that ipamorelin's selectivity profile, which is correctly described as a feature from a side effect standpoint, does create a meaningful verification disadvantage relative to GHRP-2. The pronounced orexigenic signal that GHRP-2 produces via ghrelin receptor agonism, combined with its effects on cortisol and prolactin that many researchers find undesirable, are precisely the mechanisms that provide the rapid functional readout you lose with ipamorelin. Ipamorelin's comparative selectivity for the GH secretagogue receptor with reduced off-target effects means there simply is not an equivalent acute physiological signal that fires within an hour of administration and says loudly "this compound is active."

That said, I would push back gently on the framing that sleep quality is entirely without value as an indicator. You are correct that it is a noisy variable and I would not argue otherwise. However, the pattern of sleep architecture changes is somewhat more specific than simply subjective sleep quality. Researchers using polysomnography adjacent consumer devices, and I am aware of the limitations of those devices, have noted changes in slow wave sleep duration and structure that are reasonably consistent with GH pulse augmentation during early sleep cycles. This is not a clean signal but it is more specific than "did I sleep well."

What I actually recommend in practice, and this is consistent with the broader point SupplierSkeptic99 made about establishing baselines before switching sources, is a somewhat different framing of the verification problem. Rather than looking for ipamorelin's direct functional signal, use it in combination with a low dose of GHRP-2 from a verified source as an occasional reference comparison. The combination stack allows you to retain that acute quality indicator while pursuing the cleaner primary protocol. This is admittedly an imperfect workaround.

Where I must respectfully disagree with the broader consensus forming in this thread is on the sufficiency of subjective response as a quality metric in general. Several posts here are treating the GHRP-2 hunger signal as a near-definitive quality indicator, and I think that confidence is somewhat overstated. GrumpyOldResearcher acknowledged receptor sensitivity variability but then largely proceeded past it. Inter-individual variation in ghrelin receptor expression and sensitivity is not trivial. There are documented cases where researchers with attenuated ghrelin signaling baselines show markedly blunted orexigenic response to verified, analytically confirmed GHRP-2. Using absence of that signal as near-definitive evidence of product failure, rather than one strong signal among several that should be triangulated, is the kind of reasoning that can lead to incorrect conclusions about otherwise acceptable product.

I want to be clear I am not arguing the signal is useless. I am arguing it should be weighted appropriately rather than treated as a functional assay substitute.

To directly answer your question: for ipamorelin in isolation, the honest answer is closer to your second framing. You are working with a blurrier instrument. Careful attention to sleep architecture patterns over a sufficiently long period with stable confounders controlled as much as possible is the best available substitute, but it is genuinely inferior to the acute functional readout you would have with GHRP-2. This is a real tradeoff and I appreciate that you identified it, because I do not see it discussed with sufficient candor in most ipamorelin-adjacent threads.

okay so I've been lurking this thread for like two days now reading everything very carefully and taking notes like the enormous nerd that I am, and I have a lot of thoughts so buckle up lol

biohack_bella_87 wrote:what are the reliable functional indicators for ipamorelin specifically when you're trying to evaluate product quality without access to HPLC?

okay this is literally the question I've been wanting someone to ask properly for months and I'm so glad it ended up in a thread with actual signal-to-noise ratio instead of the usual "this vendor is amazing!!!" posts from accounts made three weeks ago

so I'm going to share my experience here because I've run both GHRP-2 stacks AND ipamorelin/CJC no DAC stacks extensively and I've dealt with exactly this verification problem and I've developed what I think is a reasonably useful approach to it, caveated with all the usual "this is field anecdote not controlled data" disclaimers that dr_peptide_research would correctly insist on and honestly fair enough

the ipamorelin verification problem is real and it does have some partial solutions

so the story that I want to tell here goes back to about fourteen months ago when I made a similar switch to what biohack_bella_87 is describing - moved from GHRP-2 based stacks to ipamorelin primary because I was genuinely sick of the hunger signal disrupting my eating schedule, I'm also tracking calories reasonably carefully for body composition purposes so having a peptide that's actively screaming at my hypothalamus that I need to eat something is annoying in a practical way, not just an academic "oh I'd prefer fewer side effects" way

and immediately I felt exactly what you described - like I had given up my main quality check. because the GHRP-2 hunger hit is not subtle, it is not something you misinterpret, it fires within maybe 20-40 minutes and it is obvious. ipamorelin just... doesn't do that. which is the point. but also means you're flying differently

here's what I've actually found useful over fourteen months of paying close attention

the slow wave sleep thing is real but you have to measure it correctly

dr_peptide_research is right that sleep quality as a raw subjective metric is garbage for this purpose. "did I sleep well" is influenced by everything - your stress, your alcohol intake, whether you argued with someone at 9pm, ambient temperature, how many hours you actually got. useless. BUT. and this is the part that took me a while to figure out - if you're using any kind of consumer sleep tracker (I've used an Oura ring consistently for going on two years now, I know the limitations, I know it's not a sleep lab, I know), what you're looking for is not the sleep score. what you're looking for is deep sleep duration and timing specifically

the GH pulse pattern during early sleep cycles is fairly specific in its signature if you're watching the right thing. what I noticed with verified ipamorelin from a source I've used for eighteen months - and I did do the same kind of parallel comparison that SupplierSkeptic99 did, ran known good alongside a suspect batch - is that deep sleep stage onset timing and duration was noticeably different. not just "I felt more rested" but the actual architectural data showed changes in when deep sleep was occurring and how long it was holding

this requires like three to four weeks of data minimum, with as many confounders controlled as you can manage (consistent sleep timing, no alcohol those weeks, consistent meal timing relative to injection timing, etc). it is blurry, as biohack_bella_87 said. but it's meaningfully less blurry than pure subjective experience

the other signal I've found somewhat useful - and this is going to sound very "quantified self person" which, hi, that's me lol

morning HRV trends. again, consumer device, limitations apply, dr_peptide_research please don't come for me. but consistent HRV tracking with a stable baseline established before introducing a new source - I've seen a pattern with verified ipamorelin of measurable HRV improvement over roughly two to three weeks that is absent or attenuated with batches I ended up having quality concerns about. this is absolutely not a clean signal. there are a thousand things that affect HRV. but in the context of everything else controlled as much as possible it adds another data point

the honest truth is you're triangulating across multiple weak signals rather than having one loud obvious signal. which is inferior to the GHRP-2 hunger hit as a verification tool but it's not nothing if you're being systematic about it

GrumpyOldResearcher wrote:The cold chain piece is the part I want to underline one more time because it genuinely doesn't get enough attention. Summer transit in a bubble mailer with a joke ice pack is not a storage condition, it's a degradation condition.

okay first, I'm with biohack_bella_87 on wanting this on a t-shirt. secondly this cannot be said enough. I had a supplier once - lovely guy, seemed legit, good product history with him - and then summer hit and I got a batch that performed noticeably worse and I spent like three weeks trying to figure out if it was me, if it was the product itself, if I'd changed something. it was the shipping. I know this because he upgraded his cold pack system after I raised it and the next batch was fine. visual inspection told me literally nothing either time. lyophilized product is so deceptively normal looking even when it's been through conditions that have degraded it significantly

this is the thing I wish more newer people understood. you can open the vial, it looks great, it reconstitutes perfectly, and it can still be substantially degraded. there is no visual quality check for this. which means for summer orders specifically you need to either be paying extra attention to shipping conditions, asking vendors directly about their summer shipping protocols, or honestly building in the expectation that you might need to send back or dispute product that came in inadequate packaging in peak heat

anyway to bring this back to the main thread - SupplierSkeptic99's post was measured and responsible, gainz_peptide_bro and GrumpyOldResearcher correctly identified that waiting for HPLC before flagging anything is practically useless as community protection advice even if it's technically the more rigorous approach, and the parallel comparison method is imperfect but it's what experienced field researchers actually do and should do

very much looking forward to those HPLC results. please do update this thread when you have them because I will be following it closely

quantified_karen_lol wrote:what you're looking for is deep sleep duration and timing specifically

This is the most practical answer anyone has given to biohack_bella_87's question and it's correct. The Oura caveats are valid but a consistent multi-week trend in deep sleep architecture is a meaningfully better signal than "I felt rested." You're not measuring the absolute number, you're measuring change from your own established baseline. That's the right way to use consumer sleep data for this purpose.

The HRV point is also real. Same principle. Directional trend in a controlled window against your personal baseline. Not a clean signal but not noise either if you're being systematic.

The honest answer to biohack_bella_87's question is still that you trade acute quality feedback for a cleaner profile when you move to ipamorelin. That tradeoff is real and dr_peptide_research and quantified_karen_lol are both being straight with you about it. The verification is slower and requires more data discipline. If you're not tracking sleep architecture and HRV already, you'll want to establish at least 3-4 weeks of baseline before starting any new batch so you have something to compare against.

The triangulation approach is the answer. No single ipamorelin quality signal hits you in the face the way GHRP-2 does. You're building a case from multiple weak signals. Do it systematically or you're just guessing.